Healing · Gut · Musculoskeletal
BPC-157
Also known as: Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157, Bepecin
A 15-amino-acid synthetic peptide fragment derived from a gastric juice protein, widely promoted for soft-tissue healing despite an evidence base dominated by rodent studies.
Sign in to add to watchlistEvidence strength
Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.
Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.
Key Takeaways
- ›BPC-157 is a synthetic peptide based on a fragment of a protein found in gastric (stomach) fluid.
- ›Most of the evidence comes from animal and laboratory studies; human trials are limited and mostly date from the late 1990s and early 2000s.
- ›It is widely discussed online for healing and recovery, but those claims go well beyond what current human research supports.
- ›It is not approved by the FDA or other major regulators, and it appears on the WADA prohibited list for athletes.
- ›Long-term safety in humans has not been established. Speak with a licensed healthcare professional before making any health-related decisions.
What It Is
BPC-157 is a synthetic 15-amino-acid peptide whose sequence corresponds to a partial fragment of a larger protein identified in human gastric juice in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb. The 'BPC' designation stands for 'Body Protection Compound,' a name applied to the parent gastric protein based on observations of its broad cytoprotective effects in early rodent models.
The peptide is stable in acidic conditions, which has supported both injectable and oral routes of administration in preclinical work. Mechanistically, the proposed effects center on modulation of the nitric oxide system, angiogenesis through VEGF receptor signaling, growth-factor expression including effects on FGF and EGF pathways, and interactions with the dopaminergic and serotonergic systems in the central nervous system. The breadth of proposed mechanisms is itself a notable feature, as no single high-affinity receptor or canonical pathway has been established.
Unlock the full BPC-157 research report
Vial+ opens the mechanism breakdown, evidence graphs, potential benefits, safety considerations, regulatory status, a plain-language explainer, and 4 cited sources.
Get Vial+ — $20 one-timeLifetime access · the community forum stays free.
Disclaimer: This content is for educational and research purposes only and is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.